Radioimmunotherapy of non-Hodgkin lymphomas - PubMed (original) (raw)

Review

. 2003 Jan 15;101(2):391-8.

doi: 10.1182/blood-2002-06-1793. Epub 2002 Sep 19.

Affiliations

• PMID: 12393555
• DOI: 10.1182/blood-2002-06-1793

Free article

Review

Radioimmunotherapy of non-Hodgkin lymphomas

Bruce D Cheson. Blood. 2003.

Free article

Abstract

Enthusiasm for the use of monoclonal antibodies, such as rituximab, has markedly changed the approach to patients with non-Hodgkin lymphomas (NHLs). Nevertheless, more effective therapies are needed. Radioimmunotherapy as a form of targeted radiation therapy may add significantly to our therapeutic options. Yttrium Y 90 ibritumomab tiuxetan, recently approved by the Food and Drug Administration, and iodine I 131 tositumomab have demonstrated a high level of activity in patients whose NHL has failed to respond to chemotherapy and rituximab. Toxicities have primarily included prolonged myelosuppression, with a potential risk of treatment-associated myelodysplastic syndrome and acute myelogenous leukemia. Ongoing clinical trials are attempting to better characterize the role of these promising agents.

PubMed Disclaimer

Similar articles

• Radioimmunotherapy of non-Hodgkin's lymphomas.
  Cheson BD. Cheson BD. Curr Drug Targets. 2006 Oct;7(10):1293-300. doi: 10.2174/138945006778559157. Curr Drug Targets. 2006. PMID: 17073591 Review.
• The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
  Cheson BD. Cheson BD. BioDrugs. 2005;19(5):309-22. doi: 10.2165/00063030-200519050-00004. BioDrugs. 2005. PMID: 16207072 Review.
• Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
  Hendrix CS, de Leon C, Dillman RO. Hendrix CS, et al. Clin J Oncol Nurs. 2002 May-Jun;6(3):144-8. doi: 10.1188/02.CJON.144-148. Clin J Oncol Nurs. 2002. PMID: 11998607
• Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
  Marcus R. Marcus R. Semin Oncol. 2005 Feb;32(1 Suppl 1):S36-43. doi: 10.1053/j.seminoncol.2005.01.012. Semin Oncol. 2005. PMID: 15786024
• [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status].
  Emmanouilides C. Emmanouilides C. Rev Esp Med Nucl. 2006 Jan-Feb;25(1):42-54. doi: 10.1157/13083351. Rev Esp Med Nucl. 2006. PMID: 16540013 Review. Spanish.

Cited by

• Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers.
  Sabanathan D, Campbell DH, Velonas VM, Wissmueller S, Mazure H, Trifunovic M, Poursoltan P, Ho Shon K, Mackay TR, Lund ME, Lu Y, Roach PJ, Bailey DL, Walsh BJ, Gillatt D, Gurney H. Sabanathan D, et al. Asia Ocean J Nucl Med Biol. 2021 Spring;9(2):86-100. doi: 10.22038/AOJNMB.2021.55600.1386. Asia Ocean J Nucl Med Biol. 2021. PMID: 34250138 Free PMC article.
• Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.
  Tsao LC, Force J, Hartman ZC. Tsao LC, et al. Cancer Res. 2021 Sep 15;81(18):4641-4651. doi: 10.1158/0008-5472.CAN-21-1109. Epub 2021 Jun 18. Cancer Res. 2021. PMID: 34145037 Free PMC article. Review.
• The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule.
  Oroujeni M, Xu T, Gagnon K, Rinne SS, Weis J, Garousi J, Andersson KG, Löfblom J, Orlova A, Tolmachev V. Oroujeni M, et al. Pharmaceutics. 2021 Feb 23;13(2):292. doi: 10.3390/pharmaceutics13020292. Pharmaceutics. 2021. PMID: 33672373 Free PMC article.
• 90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma.
  Tuazon SA, Sandmaier BM, Gooley TA, Fisher DR, Holmberg LA, Becker PS, Lundberg SJ, Orozco JJ, Gopal AK, Till BG, Coffey DG, Nartea ME, Matesan MC, Pagel JM, Rajendran JG, Press OW, Bensinger WI, Green DJ. Tuazon SA, et al. Bone Marrow Transplant. 2021 Jan;56(1):202-209. doi: 10.1038/s41409-020-01000-3. Epub 2020 Jul 24. Bone Marrow Transplant. 2021. PMID: 32710011 Free PMC article. Clinical Trial.
• Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar.
  Sachpekidis C, Jackson DB, Soldatos TG. Sachpekidis C, et al. Pharmaceuticals (Basel). 2019 Sep 20;12(4):141. doi: 10.3390/ph12040141. Pharmaceuticals (Basel). 2019. PMID: 31546999 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database